Incidence Of Hepatitis In Intensive Care Unit
Incidence Of Hepatitis And Its Effect On Prognosis In Patients Who Follow In Intensive Care Unit
1 other identifier
observational
500
1 country
1
Brief Summary
The aim is to investigate incidence of HBsAg, anti-HCV in serum samples and evaluation of biomarkers taken from patients who were followed the intensive care unit of Sakarya University Training and Research Hospital and The intensive care unit attracts attention by making health workers more susceptible to the risk of hepatitis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2018
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 28, 2018
CompletedFirst Posted
Study publicly available on registry
March 7, 2018
CompletedStudy Start
First participant enrolled
April 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2019
CompletedMarch 7, 2018
March 1, 2018
1.1 years
February 28, 2018
March 6, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
HBsAg
HBsAg is the serologic hallmark of HBV infection and is the first marker to appear after acute infection.
1 month
Secondary Outcomes (1)
anti-HCV
1mounth
Interventions
There are 5 main hepatitis viruses, referred to as types A, B, C, D and E. These 5 types are of greatest concern because of the burden of illness and death they cause and the potential for outbreaks and epidemic spread. In particular, types B and C lead to chronic disease in hundreds of millions of people and, together, are the most common cause of liver cirrhosis and cancer.The aim is to investigate incidence of HBsAg, anti-HCV in serum samples and evaluation of biomarkers taken from patients who were followed the intensive care unit of Sakarya University Training and Research Hospital.
Eligibility Criteria
The study was conducted from 1 january 2015 to 1 january 2016 . Patients who were followed with various diagnoses in intensive care units between 1 january 2015 to 1 january 2016, covering the one year period, retrospectively.
You may qualify if:
- All patients who were followed in the intensive care unit
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Sakarya University Research and Training Hospital
Sakarya, 54100, Turkey (Türkiye)
Related Publications (1)
Dayan S, Tekin A, Tekin R, Dal T, Hosoglu S, Yazgan UC, Bekcibasi M, Gul K. HBsAg, anti-HCV, anti-HIV 1/2 and syphilis seroprevalence in healthy volunteer blood donors in southeastern Anatolia. J Infect Dev Ctries. 2013 Sep 16;7(9):665-9. doi: 10.3855/jidc.2835.
PMID: 24042102RESULT
Study Officials
- STUDY CHAIR
Havva Sayhan,, Assis Prof
Sakarya University Research and Training Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
February 28, 2018
First Posted
March 7, 2018
Study Start
April 1, 2018
Primary Completion
May 1, 2019
Study Completion
July 1, 2019
Last Updated
March 7, 2018
Record last verified: 2018-03